I see this as a good thing. They are focusing on what is most important right now, APAS/APAS related development and sales. When the woundvue thing came out, I was disappointed because it was so far off that I felt LBT were getting ahead of themselves when they haven't successfully commercialised APAS yet.
Ann: Strategic Plan & Asset Review, WoundVue, page-3
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $23.13M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.7¢ | $13.20K | 747.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 776749 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 238095 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| LBT (ASX) Chart |
Day chart unavailable
